Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for
early relapsed neuroblastoma. An investigational drug is one that has not yet been approved
by the Food and Drug Administration. This investigational drug is called TPI 287. This study
will look at the tumor's response to the study drug, TPI 287, in combination with Irinotecan
and Temozolomide versus the combination of Irinotecan and Temozolomide alone. This study will
also evaluate the safety and tolerability of the study drug, TPI 287.